Cardinal Health INC (CAH) — SEC Filings

Overview

Cardinal Health INC (CAH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 6, 2025: On November 5, 2025, Cardinal Health, Inc. filed an 8-K report to announce that it will hold its annual meeting of shareholders on November 5, 2025. The meeting will include the election of directors and the voting on other matters presented to the shareholders.

Sentiment Summary

Across 36 filings, the sentiment breakdown is: 3 bullish, 33 neutral. The dominant filing sentiment for Cardinal Health INC is neutral.

Filing Type Overview

Cardinal Health INC (CAH) has filed 20 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13G/A, 2 DEFA14A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (36)

• Cardinal Health Schedules Annual Shareholder Meeting — 8-K · Nov 6, 2025 Risk: low
  On November 5, 2025, Cardinal Health, Inc. filed an 8-K report to announce that it will hold its annual meeting of shareholders on November 5, 2025. The meeting
• Cardinal Health Q1 Soars on Pharma, MSO Acquisitions — 10-Q · Oct 30, 2025 Risk: medium
  Cardinal Health Inc. (CAH) reported a robust Q1 Fiscal 2026, with revenue increasing 22% to $64.0 billion, driven by strong branded and specialty pharmaceutical
• Cardinal Health Enters Material Definitive Agreement — 8-K · Oct 10, 2025 Risk: medium
  On October 7, 2025, Cardinal Health, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to th
• Cardinal Health Files 8-K for Material Agreement — 8-K · Oct 3, 2025 Risk: low
  On September 30, 2025, Cardinal Health, Inc. filed an 8-K report detailing a material definitive agreement. The filing also included financial statements and ex
• Cardinal Health Posts Double-Digit Profit Growth, Fuels Expansion with $5.3B Acquisitions — DEF 14A · Sep 16, 2025 Risk: medium
  Cardinal Health, Inc. (CAH) experienced a strong and transformative fiscal year 2025, achieving double-digit profit growth across all five operating segments. T
• Cardinal Health Enters Material Agreement, Files 8-K — 8-K · Aug 27, 2025 Risk: medium
  On August 27, 2025, Cardinal Health, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation
• Cardinal Health Files 8-K for Other Events — 8-K · Aug 14, 2025 Risk: low
  Cardinal Health, Inc. filed an 8-K on August 14, 2025, reporting on events that occurred on August 13, 2025. The filing indicates that it is a current report pu
• Cardinal Health Posts Strong FY25 Results, Revenue Hits $220.2B — 10-K · Aug 12, 2025 Risk: medium
  Cardinal Health Inc. reported robust financial performance for the fiscal year ended June 30, 2025, with revenue reaching $220.2 billion, a significant increase
• Cardinal Health Files 8-K for Regulatory Disclosures — 8-K · Jun 12, 2025 Risk: low
  On June 12, 2025, Cardinal Health, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and the filing of financial statements and
• Cardinal Health Q3 2025 Filing Released — 10-Q · May 1, 2025 Risk: low
  Cardinal Health Inc. reported its third-quarter results for the period ending March 31, 2025. The company's filing provides financial data and disclosures for t
• Cardinal Health Files 8-K on Officer/Director Changes — 8-K · Mar 10, 2025 Risk: low
  Cardinal Health, Inc. filed an 8-K on March 10, 2025, reporting events as of March 7, 2025. The filing covers the departure of directors or certain officers, th
• Cardinal Health Q2 2025 Filing — 10-Q · Jan 30, 2025 Risk: low
  Cardinal Health Inc. reported its second-quarter results for the period ending December 31, 2024. The company's filing indicates a fiscal year end of June 30th.
• Cardinal Health Files 8-K for Regulation FD Disclosure — 8-K · Jan 14, 2025 Risk: low
  On January 14, 2025, Cardinal Health, Inc. filed a Form 8-K to report a Regulation FD Disclosure. The filing does not contain specific financial figures or mate
• Cardinal Health Enters Material Definitive Agreement — 8-K · Dec 9, 2024 Risk: medium
  On December 5, 2024, Cardinal Health, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporated in Oh
• Cardinal Health Files 8-K on Agreements and Obligations — 8-K · Nov 22, 2024 Risk: medium
  On November 22, 2024, Cardinal Health, Inc. filed an 8-K report detailing the entry into and termination of material definitive agreements, as well as the creat
• Cardinal Health Files 8-K Report — 8-K · Nov 18, 2024 Risk: low
  On November 13, 2024, Cardinal Health, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specif
• Cardinal Health Enters Material Definitive Agreement — 8-K · Nov 12, 2024 Risk: medium
  On November 11, 2024, Cardinal Health, Inc. entered into a material definitive agreement. The filing also includes a Regulation FD disclosure and financial stat
• Cardinal Health Sets Shareholder Meeting Date — 8-K · Nov 7, 2024 Risk: low
  On November 6, 2024, Cardinal Health, Inc. filed an 8-K report to announce that its annual meeting of shareholders will be held on November 14, 2024. The meetin
• Cardinal Health Q1 Filing: Financials for FY25 — 10-Q · Nov 1, 2024 Risk: low
  Cardinal Health Inc. reported its first quarter results for the fiscal year ending June 30, 2025. The company's filing covers the period from July 1, 2024, to S
• SC 13G/A Filing — SC 13G/A · Oct 24, 2024
• Cardinal Health Files Proxy Materials — DEFA14A · Oct 23, 2024 Risk: low
  Cardinal Health, Inc. filed a Definitive Additional Materials proxy statement on October 23, 2024, related to its fiscal year ending June 30, 2024. This filing
• Cardinal Health Enters Material Definitive Agreement — 8-K · Oct 10, 2024 Risk: medium
  On October 8, 2024, Cardinal Health, Inc. entered into a material definitive agreement, which also created a direct financial obligation for the company. The fi
• Cardinal Health Files Proxy Statement Supplement — DEFA14A · Oct 2, 2024 Risk: low
  Cardinal Health, Inc. filed a Definitive Additional Materials proxy statement on October 2, 2024. This filing supplements previous proxy materials and concerns
• Cardinal Health Proxy: Director Elections & Executive Pay — DEF 14A · Sep 16, 2024 Risk: medium
  Cardinal Health, Inc. filed its definitive proxy statement for its 2024 Annual Meeting of Shareholders, scheduled for September 13, 2024. The filing details the
• Cardinal Health Appoints New Directors and Officers — 8-K · Sep 9, 2024 Risk: low
  Cardinal Health, Inc. announced on September 6, 2024, changes in its executive and director roles. The company elected two new directors, Michael J. Gregoire an
• Cardinal Health Files 2024 10-K — 10-K · Aug 14, 2024 Risk: medium
  Cardinal Health Inc. filed its 10-K for the fiscal year ending June 30, 2024. The company, headquartered in Dublin, Ohio, operates in the wholesale distribution
• Cardinal Health Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 2, 2024 Risk: low
  CARDINAL HEALTH INC (CAH) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Cardinal Health Inc. filed a 10-Q report for the period ending March 31,
• Cardinal Health Files 8-K — 8-K · Apr 23, 2024 Risk: low
  On April 23, 2024, Cardinal Health, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No s
• Cardinal Health Files 8-K: Regulation FD & Financials — 8-K · Apr 22, 2024 Risk: low
  On April 22, 2024, Cardinal Health, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No spec
• Cardinal Health Files 8-K on Officer Changes, Compensation — 8-K · Feb 28, 2024 Risk: medium
  Cardinal Health, Inc. filed an 8-K on February 28, 2024, reporting on potential changes in directors or certain officers, their election or appointment, and rel
• Cardinal Health Enters Material Agreement & Financial Obligation — 8-K · Feb 20, 2024 Risk: medium
  Cardinal Health, Inc. filed an 8-K on February 20, 2024, reporting an event that occurred on February 14, 2024. The filing indicates the entry into a material d
• Vanguard Group Amends Cardinal Health Stake, Maintains Passive Position — SC 13G/A · Feb 13, 2024 Risk: low
  The Vanguard Group, a major investment management company, filed an amended SC 13G/A on February 13, 2024, disclosing its ownership of Cardinal Health Inc. comm
• Cardinal Health Inc. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 1, 2024 Risk: low
  CARDINAL HEALTH INC (CAH) filed a Quarterly Report (10-Q) with the SEC on February 1, 2024. Cardinal Health Inc. filed its quarterly report (10-Q) for the perio
• State Street Amends Cardinal Health Stake, Signals Passive Holding — SC 13G/A · Jan 30, 2024
  State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 30, 2024, disclosing its ownership of Cardinal Health Inc. common
• BlackRock Updates Passive Stake in Cardinal Health (CAH) — SC 13G/A · Jan 24, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating its ownership of Cardinal Health Inc. common stock as of December 31, 2023. This filing
• Cardinal Health 8-K Signals Financial Update, Regulation FD Disclosure — 8-K · Jan 9, 2024
  Cardinal Health, Inc. filed an 8-K on January 9, 2024, to report on 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure.' This filing

Risk Profile

Risk Assessment: Of CAH's 32 recent filings, 0 were flagged as high-risk, 13 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Cardinal Health INC's most recent 10-Q filing (Oct 30, 2025):

• Revenue: $64.0B
• Net Income: $668M
• EPS: $1.88
• Cash Position: $4.6B

Key Executives

• Robert Musslewhite
• Sudhakar Ramakrishna
• Gregory B. Kenny
• Michael J. Gregoire
• Dr. Steven J. Corbat
• William J. Klippert
• Dr. Samuel J. Nussbaum

Industry Context

Cardinal Health operates in the pharmaceutical distribution and medical product manufacturing sectors, a highly competitive and regulated industry. Key trends include the increasing demand for specialty pharmaceuticals, the growing importance of MSO platforms in healthcare delivery, and the ongoing scrutiny of drug pricing. The company's strategy involves strategic acquisitions to expand its service offerings and market reach.

Top Tags

material-agreement (5) · 10-Q (5) · regulation-fd (5) · corporate-governance (4) · financial-obligation (4) · regulatory-filing (4) · 8-K (3) · financials (3) · material-definitive-agreement (3) · sec-filing (3)

Executive Compensation

From the most recent DEF 14A filing (Sep 16, 2025):

• Not Specified — Named Executive Officers: Not Specified

Key Numbers

• Total Revenue: $64.0B — Increased 22% from prior-year quarter
• GAAP Operating Earnings: $668M — Increased 18% from prior-year quarter
• Non-GAAP Operating Earnings: $857M — Increased 37% from prior-year quarter
• GAAP Diluted EPS: $1.88 — Increased 11% from prior-year quarter
• Non-GAAP Diluted EPS: $2.55 — Increased 36% from prior-year quarter
• Pharmaceutical and Specialty Solutions Revenue: $59.2B — Increased 23% from prior-year quarter
• Pharmaceutical and Specialty Solutions Profit: $667M — Increased 26% from prior-year quarter
• Solaris Health Acquisition Price: $1.9B — Cash purchase price for MSO platform
• Cash and Equivalents: $4.6B — Balance at September 30, 2025, up from $3.9 billion at June 30, 2025
• Net Cash Provided by Operating Activities: $1.0B — For the three months ended September 30, 2025
• Report Date: 2025-09-30 — Date of the earliest event reported in the 8-K
• Revenue: $222.6B — Down 2% year-over-year due to OptumRx contract expiration
• Operating Cash Flow: $2.4B — Down 37% year-over-year, reflecting impact of unwinding negative net working capital from OptumRx contracts
• Acquisition Deployment: $5.3B — Invested in MSO platforms in Specialty and at-Home Solutions growth strategy
• Returned to Shareholders: $1.2B — Comprised of $750 million in share repurchases and $494 million in dividends

Related Companies

CVS · MCK · ABC

Frequently Asked Questions